AGP Picks
View all

SpringRA helped secure FDA clearance for Levo’s software-only tinnitus therapy

9 hours ago
SpringRA helped secure FDA clearance for Levo’s software-only tinnitus therapy
By AI, Created 18:39 UTC, Nov 16, 2026, AGP -

Levo Medical Corporation’s Levo Gen 2 Tinnitus Therapy System won FDA 510(k) clearance on Aug. 13, 2026, opening U.S. access to a remote, software-based treatment for adults with tinnitus. Toronto consultancy SpringRA led the submission, documentation and FDA responses behind the clearance.

Why it matters: - Levo Gen 2 expands access to tinnitus care with a software-only treatment that can be delivered remotely. - The FDA clearance gives Levo Medical Corporation a broader U.S. market for adult patients seeking non-hardware therapy. - Tinnitus affects about 1 in 10 U.S. adults, or an estimated 21.4 million people, in a given year. - For many patients, tinnitus disrupts sleep, concentration and emotional wellbeing.

What happened: - Levo Medical Corporation received FDA 510(k) clearance for Levo Gen 2 Tinnitus Therapy System on Aug. 13, 2026, under K260413. - The clearance covers adult patients seeking software-based, remote-delivered tinnitus relief. - SpringRA, a Toronto regulatory consultancy, managed the authorization process end to end. - SpringRA handled the software documentation, the submission and post-submission communication with the FDA. - SpringRA served as correspondent of record on the submission, with principal consultant Tal Bresler Stramer listed as contact. - The work started in September 2025 and took about a year.

The details: - Levo Gen 2 is a software-only device. - The system combines individualized sound masking with a CBT-based habituation program. - The first-generation Levo System was cleared in 2014 and used sound masking with dedicated hardware. - The FDA submission included more than 30 documents. - Those documents covered cybersecurity, auditory safety and psychological safety. - The FDA required patient data to stay inside Levo’s own ecosystem. - Levo used its own AI agent to process patient data instead of routing data through a third-party model. - SpringRA guided and wrote the software development lifecycle documentation. - SpringRA built the evidence package for premarket review across cybersecurity, auditory safety and psychological safety. - SpringRA composed the 510(k) submission documents. - SpringRA prepared responses to the FDA’s Additional Information request. - SpringRA also facilitated a Submission Issue Request to communicate with the agency. - Tal Bresler Stramer led a multidisciplinary team of subject matter experts from Levo and SpringRA. - The team worked alongside Levo’s engineering and clinical teams. - Levo CEO Daniel Drexler said the submission was extremely complex because it covered every aspect of the treatment.

Between the lines: - The clearance suggests FDA review standards for digital therapies are extending beyond basic software function into cybersecurity, data handling and psychological safety. - A software-only model may make tinnitus treatment easier to scale than hardware-based systems. - The move away from dedicated hardware also points to a shift toward remote care delivery. - SpringRA’s role shows how regulatory consultants can shape both the technical documentation and the FDA process for software as a medical device.

What's next: - Levo Medical Corporation can now push further into the U.S. market for adult tinnitus care. - The company’s remote-delivered model may support broader adoption if patients and clinicians accept software-based therapy. - SpringRA says it supports FDA, Health Canada and EU MDR submissions, including 510(k)s and software as a medical device documentation. - More information is available in the full case study.

The bottom line: - SpringRA’s FDA work helped clear a software-only tinnitus therapy that could widen access to treatment for millions of U.S. adults.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

IT Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

IT Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.